ReviewGastrointestinal endoscopy clinics of North America2026
Emerging Biomarkers for Managing Barrett's Esophagus.
Pakdee Rojanasopondist, Andrew Kaz, Ming Yu, William M Grady
Abstract readReview
In one paragraphReview in Gastrointestinal endoscopy clinics of North America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
4 authors.
Pakdee RojanasopondistDepartment of Internal Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356421, Seattle, WA 98195-6421, USA.
Andrew KazUniversity of Washington School of Medicine, Seattle, WA, USA; Gastroenterology Section, VA Puget Sound Health Care System, 1660 S. Columbian Way, S-111-Gastro, Seattle, WA 98108, USA.
Ming YuDepartment of Internal Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356421, Seattle, WA 98195-6421, USA; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, 1100 Fairview Avenue N, D4-100, Seattle, WA 98109, USA.
William M GradyDepartment of Medicine, University of Washington School of Medicine, Seattle; Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle. Electronic address: wgrady@fredhutch.org.
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MIdentify and validate novel epigenetic molecular markers for colorectal neoplasmU01CA152756 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY, GUDA, KISHORE · 2010 to 2021
$6.7MBiomarkers for optimizing risk prediction and early detection of cancers of the colon and esophagusU2CCA271902 · NCI · FRED HUTCHINSON CANCER CENTER · PI Cecilia C Yeung · 2022 to 2026
$5.3MGenetics, Epigenetics, and Risk Prediction for Esophageal AdenocarcinomaR01CA266386 · NCI · FRED HUTCHINSON CANCER CENTER · PI BUAS, MATTHEW FRANK, KOOPERBERG, CHARLES L · 2022 to 2025
$3.6MTranslational Science of Gastrointestinal Cancer Initiation and ProgressionR50CA233042 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Ming Yu · 2018 to 2026
$2.4MMultiscale modeling of spatiotemporal evolution in Barrett's esophagusR01CA270235 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Kathleen M. Curtius · 2023 to 2026
$2.3MThe microbiome ecosystem of Barrett's esophagus and progression to cancerR21CA259687 · NCI · FRED HUTCHINSON CANCER CENTER · PI PAULSON, THOMAS G · 2022 to 2023
$407kNCI NIH HHS P30 CA015704NCI NIH HHS R01 CA266386NCI NIH HHS R01 CA270235NCI NIH HHS R21 CA259687NCI NIH HHS R50 CA233042NCI NIH HHS U01 CA152756NCI NIH HHS U2C CA271902
6 · The paper itselfAbstract
Comparative analyses of normal esophageal tissue, Barrett's Esophagus (BE), and esophageal adenocarcinoma have identified distinctive molecular alterations in genomic DNA, epigenetics, non-coding RNA, and proteins that have shown promise as disease-specific biomarkers. Some of the best characterized and promising biomarkers for managing BE are multi-target esophageal cytology DNA assays based on methylated-DNA and immunohistochemical staining of Trefoil factor 3. Additional biomarkers including microRNA, measures of genomic instability, mixed-method panels, and other novel biomarkers (e.g. volatile organic compounds and saliva microbiome) remain in early development and will need further validation in large, prospective studies prior to clinical use.
Indexed as
AdenocarcinomaBarrett EsophagusBiomarkers, TumorEsophageal NeoplasmsBiomarkersDNA MethylationHumansMicroRNAsBiomarkersBiomarkers, TumorMicroRNAsBarrett’s esophagusEarly detectionEsophageal adenocarcinomaMolecular biomarkersRisk prediction
Identifiers
PMID41260765
PMCPMC13623394
What OpenQuestion holds
Textmetadata
Read underepoch 390